51st Annual Meeting & ToxExpo - Society of Toxicology

Society of Toxicology 2012
Exhibitor Hosted Sessions
Exhibits
TUESday
Development Challenges for Antibody Drug
Conjugates (ADCs)
Tuesday, March 13, 8:30 AM–9:30 AM
Presented by:
MPI Research
ADCs combine the targeting potential of mAbs with the pharmacology
of small molecules. These are significant challenges in the
development of ADCs such as lot variation as well as the need to
simultaneously determine safety margins for intact ADC, drug-free
mAb, and small molecules that are released in vivo.
Human Induced Pluripotent Stem Cell Technology
in Predictive and Mechanism-Based Drug
Discovery and Toxicity Testing Using Photometric-
Based Assays
Tuesday, March 13, 8:30 AM–9:30 AM
Presented by:
Promega Corporation
Human iPSC-technology and photometric assays provide rapid and
predictive assessments of viability/toxicity and ADME properties
during drug development. This tutorial will highlight recent developments
in human iPSC-derived cell types from CDI and reporter assays
from Promega while demonstrating the advantages of these technologies
in accurate assessment of drug-induced cellular responses.
Current Strategies for Juvenile Toxicity Testing
Tuesday, March 13, 9:45 AM–10:45 AM
Presented by:
Charles River
Since issuance of the pediatric rule 14 years ago, we have conducted
over 300 juvenile toxicity studies in rodent and nonrodent animals
for numerous therapeutics (large and small molecule) and chemicals.
This seminar will cover what we have learned, current global regulatory
expectations, and program designs including species, dose routes,
and evaluation.
Experience Results: Lessons Learned Developing
New Anticancer Drugs and Biotherapeutics
Tuesday, March 13, 9:45 AM–10:45 AM
Presented by:
Accelera Srl
Case stories from the direct experience of safety assessment for
different drug development programs, including some marketed
products, are presented with special emphasis on anticancer drugs
and biotherapeutics. Challenges, key issues, and lessons learned are
described in the context of scientific and regulatory requirements.
Developing a Novel Gene Therapy Product
for the Treatment of Rare X-Linked Disease
Tuesday, March 13, 9:45 AM–10:45 AM
Pathology Peer Review: Who, What, When, Where,
Why, and How
Tuesday, March 13, 8:30 AM–9:30 AM
Presented by:
Vet Path Services
This presentation will cover pathology peer review in the industrial,
GLP setting, with discussions of who does a peer review, what the peer
review achieves, when it is performed, why should a peer review be
done, and how a pathologist goes about a peer review. It will highlight
current common practices in the current regulatory environment.
Presented by:
Huntingdon Life Sciences
Safety assessment of gene therapy products is a complex business
with multiple safety risks. Standard paradigms do not exist and
approaches must be designed on a case-by-case basis. A case study will
be discussed that highlights considerations for a gene therapy to treat
an x-linked disease.
Innovative Models and Techniques
for the Investigation of Nanotoxicity
Tuesday, March 13, 11:00 AM–12:00 Noon
Presented by:
Fraunhofer ITEM
The session will focus on the state of the art and future of in vivo inhalation
tests, innovative in vitro and ex vivo models as significant tools
in inhalation toxicology, and sensitive methods to detect lung damage
potentially induced by nanoparticles including carbonanotubes.
118
SOT’s 51 st Annual Meeting